In PAN, ESR and MMP-3 showed significant changes during active disease regardless of treatment, and in EGPA, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) IL-6, IL-15, and sIL-2Rα showed significant increases during active disease, as did B cell-attracting chemokine (BCA)-1/CXCL13 but only after adjustment for treatment [71]. The gene discussed is CXCL13; the disease is polyarteritis nodosa.